39604-69-8

Usage

Preparation

Preparation by partial methylation of 2,4-di-methoxybenzyl 2,4,6-trihydroxyphenyl ketone with dimethyl sulfate in the presence of potassium carbonate in boiling acetone.

Upstream product

• 1100-15-8 5,7,2',4'-tetramethoxyisoflavone 
• 1100-14-7 3-(2,4-dimethoxy-phenyl)-5,7-dimethoxy-chroman-4-one 
• 621-23-8 1,2,3-trimethoxybenzene 
• 6496-89-5 2,4-dimethoxyphenylacetic acid 
• 139445-84-4 (2,4-dimethoxy-phenyl)-acetyl chloride 
• 65568-08-3 2-(2,4-dimethoxyphenyl)-1-(2,4,6-trihydroxyphenyl)-ethanone 
• 77-78-1 dimethyl sulfate 
• 521291-07-6 2,4,6,2',4'-pentamethoxy-deoxybenzoin 

Downstream Products

• 61503-84-2 3-(2',4'-dimethoxyphenyl)-4-hydroxy-5,7-dimethoxy-2H-1-benzopyrane-2-one 
• 88092-57-3 1-(2,4-Dimethoxy-phenyl)-2-(2-hydroxy-4,6-dimethoxy-phenyl)-ethane-1,2-dione 
• 88092-58-4 2-(2,4-Dimethoxy-phenyl)-2,4,6-trimethoxy-benzofuran-3-one 
• 1100-15-8 5,7,2',4'-tetramethoxyisoflavone 
• 32884-36-9 5,2',4'-trihydroxy-7-methoxyisoflavone 
• 98094-87-2 Lupinalbin A 
• 1156-78-1 2',4',5,7-tetrahydroxyisoflavone 
• 521291-07-6 2,4,6,2',4'-pentamethoxy-deoxybenzoin 
• 1100-14-7 3-(2,4-dimethoxy-phenyl)-5,7-dimethoxy-chroman-4-one 
• 111161-81-0 4-acetoxy-3-(2,4-dimethoxy-phenyl)-5,7-dimethoxy-coumarin 

Relevant academic research and scientific papers

Total synthesis of apios isoflavones and investigation of their tyrosinase inhibitory activity

Apios isoflavone glucosides 1 and 2 were synthesized for the first time via Friedel–Crafts reaction, Bischler–Napieralski-type cyclization, and phase-transfer catalyzed glycosylation as the key steps. In addition, aglycones 4 and 5 and related natural iso

Constrained phytoestrogens and analogues as ERβ selective ligands

A new series of ERbeta (ERβ) selective ligands has been prepared. One of the compounds 6, structurally related to the phytoestrogen apigenin 4, displays a binding preference for ERβ over ERα of over 40-fold. In addition to its binding selectivity, 6 was a

Substituted 10,11-benzo[b]fluoren-10-ones as estrogenic agents

This invention provides estrogen receptor modulators of formula 1, having the structure wherein X, Y1, Y2, Y3, Y4, Z1, Z2, Z3, and Z4 are as defined in the specificati